Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HMPL-523 in Healthy Volunteers
NCT02105129Phase 1Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- May 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in rheumatoid arthritis (RA) comparing HMPL-523 with Placebo (2 arms). Primary endpoint: Number of participants with adverse events at 6 months. Started May 2014; status: completed.
02
Drugs
sovleplenib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02105129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02105129.